These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 38952638)
1. The Comparison of Irisin, Subfatin, and Adropin in Normal-Weight and Obese Polycystic Ovary Syndrome Patients. Majeed AA; Al-Qaisi AHJ; Ahmed WA Iran J Med Sci; 2024 Jun; 49(6):350-358. PubMed ID: 38952638 [TBL] [Abstract][Full Text] [Related]
2. Adropin in women with polycystic ovary syndrome. Kuliczkowska-Płaksej J; Mierzwicka A; Jończyk M; Stachowska B; Urbanovych A; Bolanowski M Endokrynol Pol; 2019; 70(2):151-156. PubMed ID: 30480749 [TBL] [Abstract][Full Text] [Related]
3. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Inal ZO; Erdem S; Gederet Y; Duran C; Kucukaydin Z; Kurku H; Sakarya DK Endokrynol Pol; 2018; 69(2):135-141. PubMed ID: 29465156 [TBL] [Abstract][Full Text] [Related]
4. Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome. Cao S; Hu Y Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34427289 [TBL] [Abstract][Full Text] [Related]
5. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233 [TBL] [Abstract][Full Text] [Related]
6. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. Kume T; Calan M; Yilmaz O; Kocabas GU; Yesil P; Temur M; Bicer M; Calan OG J Endocrinol Invest; 2016 Jul; 39(7):747-54. PubMed ID: 26969461 [TBL] [Abstract][Full Text] [Related]
7. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women? Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816 [TBL] [Abstract][Full Text] [Related]
8. Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. Wang W; Guo Y; Zhang X; Zheng J Clin Endocrinol (Oxf); 2018 Oct; 89(4):474-480. PubMed ID: 29972694 [TBL] [Abstract][Full Text] [Related]
9. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380 [TBL] [Abstract][Full Text] [Related]
10. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Adamska A; Karczewska-Kupczewska M; Lebkowska A; Milewski R; Górska M; Otziomek E; Nikolajuk A; Wolczynski S; Kowalska I Endocr J; 2016 Dec; 63(12):1107-1112. PubMed ID: 27616010 [TBL] [Abstract][Full Text] [Related]
11. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. Chang CL; Huang SY; Soong YK; Cheng PJ; Wang CJ; Liang IT J Clin Endocrinol Metab; 2014 Dec; 99(12):E2539-48. PubMed ID: 25029417 [TBL] [Abstract][Full Text] [Related]
12. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]. Li X; Lin JF Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817 [TBL] [Abstract][Full Text] [Related]
13. Adropin levels and its associations as a fat-burning hormone in patients with polycystic ovary syndrome: a correlational meta-analysis. Varikasuvu SR; Reddy EP; Thangappazham B; Varshney S; Das VL; Munikumar M Gynecol Endocrinol; 2021 Oct; 37(10):879-884. PubMed ID: 34241553 [TBL] [Abstract][Full Text] [Related]
14. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Yildirim B; Celik O; Aydin S Clin Exp Obstet Gynecol; 2014; 41(3):310-2. PubMed ID: 24992783 [TBL] [Abstract][Full Text] [Related]
15. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. Li L; Chen X; He Z; Zhao X; Huang L; Yang D J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573 [TBL] [Abstract][Full Text] [Related]
16. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948 [TBL] [Abstract][Full Text] [Related]
17. Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. Bousmpoula A; Kouskouni E; Benidis E; Demeridou S; Kapeta-Kourkouli R; Chasiakou A; Baka S Gynecol Endocrinol; 2018 Feb; 34(2):153-156. PubMed ID: 28937295 [TBL] [Abstract][Full Text] [Related]
18. Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome. Olszanecka-Glinianowicz M; Madej P; Owczarek A; Chudek J; Skałba P Clin Endocrinol (Oxf); 2015 Jul; 83(1):98-104. PubMed ID: 25440474 [TBL] [Abstract][Full Text] [Related]
20. Free androgen index and Irisin in polycystic ovary syndrome. Li H; Xu X; Wang X; Liao X; Li L; Yang G; Gao L J Endocrinol Invest; 2016 May; 39(5):549-56. PubMed ID: 26584566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]